The Stanly News and Press (Albemarle, NC)

State & National News

March 6, 2014

Lilly's diabetes drug rejected by FDA

Thursday, March 6, 2014 — A diabetes pill developed by Eli Lilly and Boehringer Ingelheim was rejected by U.S. regulators because of previously disclosed manufacturing deficiencies at a German plant that hadn't been resolved.

The Food and Drug Administration inspected Boehringer's Ingelheim am Rhein facility in 2012 and warned the Ingelheim- based company of the faults in May 2013. No new clinical studies will be needed to approved the drug, called empagliflozin, the companies said Wednesday in a statement.

"The complete response letter referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured," the companies said. The FDA won't approved the drug until the problems are fixed.

About 24 million people in the United States have diabetes, a condition often driven by obesity where the body loses its ability to process sugar.

Empagliflozin is part of a class of drugs that includes Johnson & Johnson's Invokana and AstraZeneca's Forxiga. The drugs help the body get rid of sugar through the kidneys.

The Lilly-Boehringer drug is projected to sell $295 million for Lilly in 2019, according to analyst estimates compiled by Bloomberg.

The FDA re-inspection of Boehringer's plant is continuing, said Emily Baier, a spokeswoman for the company. "The inspection is reviewing aspects related to production, processes, quality assurance and other related areas," said in an email. It could take up to six months after the inspection for the FDA to decide whether the problems have been fixed.

The 2012 inspection found what the FDA called "significant violations of current manufacturing practice" at the plant. They included a failure to look into issues with the active ingredients of drug made there as well as contamination problems that also weren't investigated.

The warning letter last year didn't specifically mention empagliflozin, Philip Johnson, Lilly's vice president of investor relations, said on a Jan. 7 conference call.

"Empagliflozin was not specifically cited in that warning letter," Johnson said. "There was other commercial production that was specifically referenced. Boehringer Ingelheim has been working through this with the FDA."



 

1
Text Only
State & National News
  • linda-ronstadt.jpg Obama had crush on First Lady of Rock

    Linda Ronstadt remained composed as she walked up to claim her National Medal of Arts at a White House ceremony Monday afternoon.

    July 29, 2014 1 Photo

  • Brother sues W.Va. senator over business loan

    FAIRMONT, W. Va. - U.S. Sen. Joe Manchin's brother claims he's owed $1.7 million that he loaned to keep a family carpet out of bankruptcy in the 1980s.

    July 28, 2014

  • CATS-DOGS281.jpg Where cats are more popular than dogs in the U.S.-and all over the world

    We all know there are only two types of people in the world: cat people and dog people. But data from market research firm Euromonitor suggest that these differences extend beyond individual preferences and to the realm of geopolitics: it turns out there are cat countries and dog countries, too.

    July 28, 2014 1 Photo

  • WORLD NEWS: Fast food comes to standstill in China

    BEIJING - The shortage of meat is the result of China's latest food scandal, in which a Shanghai supplier allegedly tackled the problem of expired meat by putting it in new packaging and shipping it to fast-food restaurants around the country

    July 28, 2014

  • Facebook continues moneymaking trend

    WASHINGTON - Facebook seems to have figured out - for now at least - the holy grail for all media right now: how to make money selling mobile ads.

    July 25, 2014

  • Arizona's prolonged lethal injection is fourth in U.S. this year

    NEW YORK - Arizona's execution of double-murderer Joseph Wood marked the fourth time this year that a state failed to dispatch a convict efficiently, according to the Constitution Project, a bipartisan legal group.

    July 25, 2014

  • N.C. Energy Policy Council Long Range Energy Generation and Renewable Energy Committee to meet

    RALEIGH – The North Carolina Energy Policy Council’s Long Range Energy Generation and Renewable Energy Committee will meet via conference call at 9 a.m. July 31.

    July 24, 2014

  • N.C. State University Turfgrass Field Day set for Aug. 13

    N.C. State University’s annual Turfgrass Field Day will be held in Raleigh at the Lake Wheeler Turfgrass Research Lab, Aug. 13, 8:30 a.m. - 2 p.m. One of the largest events of its kind in the country, the field day offers the industry and general public a chance to view the Turfgrass Program’s ongoing research trials and speak directly with N.C. State faculty and staff.

    July 24, 2014

  • NCSU Study: Urban Heat Boosts Some Pest Populations 200-Fold, Killing Red Maples

                New research from North Carolina State University shows that urban “heat islands” are slowly killing red maples in the southeastern United States. One factor is that researchers have found warmer temperatures increase the number of young produced by the gloomy scale insect – a significant tree pest – by 300 percent, which in turn leads to 200 times more adult gloomy scales on urban trees.

    July 23, 2014

  • An oncologist uses scorpion venom to locate cancer cells

    Olson, a pediatric oncologist and research scientist in Seattle, has developed a compound he calls Tumor Paint. When injected into a cancer patient, it seems to light up all the malignant cells so surgeons can easily locate and excise them.

    July 22, 2014

House Ads
Seasonal Content